908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook
07 Nov 2023
Financial Statement
BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023.
"We are pleased with the step-up in our revenues from the second quarter and the positive growth trend over the past nine months, despite the challenging environment in the life sciences instrumentation and bioprocessing markets," said Kevin J. Knopp, CEO and Co-founder. "Handheld revenue grew 19% year to date and we expect that to further accelerate in the fourth quarter. This underscores the value our handheld devices bring to our customers, aiding them in enhancing public safety during the ongoing crises of counterfeit drugs and opioids. Our expanding range of products and diverse markets are key strengths for 908 Devices, positioning us for success over the near and long term."
Third Quarter 2023 Financial Highlights
Revenue of $35.9 million for the first nine months of 2023, increasing 2% compared to first nine months of 2022
Revenue of $14.3 million for the third quarter 2023, decreasing 9% compared to the third quarter 2022
Handheld revenue was $11.7 million
Desktop revenue was $2.5 million
Recurring revenue was $3.6 million
Ended the third quarter 2023 with $148 million in cash, cash equivalents and marketable securities with no debt outstanding, decreasing $5 million compared to prior quarter end
Recent Operating Highlights
Launched MAVERICK in September for real-time in-line monitoring of multiple bioprocess parameters
Entered initial production phase of US Department of Defense Aerosol and Vapor Chemical Agent Detector program to produce 122 initial systems, with partner Smiths Detection
Received $10.4 million in orders from the United States Air Force for MX908 devices, Aero accessories, and support and recognized $4.2 million in the third quarter 2023
Announced a collaboration with Terumo Blood and Cell Technologies for integrating our MAVEN on-line analyzer with Terumo BCT’s Quantum Flex cell therapy expansion platform
Third Quarter 2023 Financial Results
Revenue was $14.3 million for the three months ended September 30, 2023, a 9% decrease over the prior year period. This was primarily driven by a decline in desktop devices and handheld recurring revenue. The installed base grew to 2,714 devices with 124 devices placed during the third quarter 2023.
Recurring revenue represented 25% of total revenues in the quarter. Recurring revenue declined $0.9 million to $3.6 million over the prior year period. This was driven by a decline in handheld accessory and consumable revenue, offset in part by growth in service revenue.
Gross profit was $7.9 million for the third quarter of 2023, compared to $9.3 million for the corresponding prior year period. Gross margin was 55% as compared to 59% for the corresponding prior year period. The decline in gross margin was largely due to the decrease in revenues as well as higher service costs with training obligations, charges for excess and obsolete inventory, and the higher non-cash charges for intangible amortization and stock-based compensation during the third quarter of 2023.
Operating expenses were $17.0 million for the third quarter of 2023, compared to $16.5 million for the corresponding prior year period. This increase was driven by stock-based compensation and an increase in acquisition related costs for intangible amortization and valuation of contingent milestones, offset in part by a reduction in general operating costs.
Net loss was $7.1 million for the third quarter of 2023, compared to $6.3 million for the corresponding prior year period. Net loss per share was $0.22 for the third quarter of 2023, compared to a net loss per share of $0.20 for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $148 million as of September 30, 2023.
2023 Guidance
908 Devices now expects full year 2023 revenue to be in the range of $49 million to $51 million, representing 4% to 9% growth over full year 2022, which compares to its previous expectations of $49 million to $52 million.
Webcast Information
908 Devices will host a conference call to discuss the third quarter 2023 financial results before market open on Tuesday, November 7, 2023 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at . The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at . Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
908 DEVICES INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
2023
2022
2023
2022
Revenue:
Product revenue
$
12,161
$
13,541
$
28,778
$
29,169
Service revenue
2,136
1,896
6,730
4,905
Contract revenue
—
360
370
1,135
Total revenue
14,297
15,797
35,878
35,209
Cost of revenue:
Product cost of revenue
4,651
5,234
13,237
11,509
Service cost of revenue
1,777
1,132
4,495
3,259
Contract cost of revenue
—
93
99
340
Total cost of revenue
6,428
6,459
17,831
15,108
Gross profit
7,869
9,338
18,047
20,101
Operating expenses:
Research and development
5,537
4,666
16,460
12,864
Selling, general and administrative
11,421
11,826
34,632
32,281
Total operating expenses
16,958
16,492
51,092
45,145
Loss from operations
(9,089
)
(7,154
)
(33,045
)
(25,044
)
Other income, net
1,909
895
3,866
1,272
Loss from operations before income taxes
(7,180
)
(6,259
)
(29,179
)
(23,772
)
Benefit from income taxes
87
—
209
—
Net loss
$
(7,093
)
$
(6,259
)
$
(28,970
)
$
(23,772
)
Net loss per share attributable to common stockholders
$
(0.22
)
$
(0.20
)
$
(0.90
)
$
(0.76
)
Weighted average common shares outstanding
32,345,925
31,606,484
32,171,685
31,441,611
908 DEVICES INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
September 30,
December 31,
2023
2022
Assets
Current assets:
Cash, cash equivalents and marketable securities
$
147,897
$
188,422
Accounts receivable, net
12,885
10,033
Inventory
15,926
12,513
Prepaid expenses and other current assets
3,119
4,658
Total current assets
179,827
215,626
Operating lease, right-of-use assets
6,677
3,956
Property and equipment, net
2,854
3,083
Goodwill
9,928
10,050
Intangible, net
7,742
8,488
Other long-term assets
1,447
1,384
Total assets
$
208,475
$
242,587
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses
$
9,848
$
10,244
Deferred revenue
10,521
7,514
Operating lease liabilities
1,953
1,468
Total current liabilities
22,322
19,226
Long-term debt, net of discount and current portion
—
15,000
Deferred revenue, net of current portion
4,447
3,040
Other long-term liabilities
11,777
14,722
Total liabilities
38,546
51,988
Total stockholders' equity
169,929
190,599
Total liabilities and stockholders' equity
$
208,475
$
242,587
View source version on businesswire.com:
Contacts
Investors:
Carrie Mendivil
IR@908devices.com
Media:
Barbara Russo
brusso@908devices.com
Source: 908 Devices Inc.
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.